Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did.
Proposing that prescription requirements and telehealth models deserves a maintained page rather than a recurring topic, and drafting the skeleton here so that the argument about scope happens before the writing rather than after.
What I think belongs on it, what does not, and the three claims that would need a citation each.
Narrowing the opening post, because the general version has more than one answer.
Trying to state the prescription requirements and telehealth models position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Distinguishing three things in the prescription requirements and telehealth models discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.
On reflection I would soften that slightly.
Answering the question the opening post raises rather than the one it answers.
Having read the whole prescription requirements and telehealth models thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
That is the distinction I keep failing to hold on to. Written down now.
Prescription requirements and telehealth models is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.
I have changed my mind on this once already, so take it as current rather than settled.
I think the prescription requirements and telehealth models question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Post #10 is right about the mechanism and I think understates the practical bit.
I would be cautious about generalising from the prescription requirements and telehealth models example above. It is a good example. It is one example.
Picking up post #14: that is the part I would want checked first.
Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.
Prescription requirements and telehealth models: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
I had written a reply contradicting post #16 and deleted it. Here is what survived.
Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.
That is a description of practice, not a recommendation of it.
Building on post #18 rather than restating it.
The documentation on prescription requirements and telehealth models is better than this thread and I say that as someone who has posted in the thread.
Reframing prescription requirements and telehealth models slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
Something worth flagging about prescription requirements and telehealth models: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
On post #21 — agreed on the reasoning, with one qualification.
An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.
Anyone who has looked at this more carefully, please correct the record.
Picking up post #21: that is the part I would want checked first.
Prescription requirements and telehealth models has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Post #24 answers the question as asked. The question underneath it is different.
Offering a way to settle prescription requirements and telehealth models rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.
Everything in post #26 holds. The case it does not cover is the one I have.
The reason prescription requirements and telehealth models is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
Two sentences on prescription requirements and telehealth models and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.